We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Therapy Techniques Contributed to a Decrease in Cancer Rates

By Biotechdaily staff writers
Posted on 06 Nov 2007
Professional radiology societies in the United States are encouraged by a recent report that credits improved screening techniques and more effective treatment for the noticeable decline in U.S. More...
cancer mortality rates.

The American College of Radiology (ACR; Reston, VA, USA), through its clinical trials research groups, the American College of Radiology Imaging Network (ACRIN) and the Radiation Therapy Oncology Group (RTOG), has conducted research in diagnostic imaging and radiation therapy for nearly 40 years and is one of the largest National Cancer Institute- (NCI)-funded clinical research organizations in the country.

The report, called Annual Report to the Nation on the Status of Cancer, was created by the American Cancer Society, the U.S. Centers for Disease Control and Prevention, the U.S. National Cancer Institute, and the North American Association of Central Cancer Registries.

"The ACR is proud of the research coordinated by our cooperative groups and by other institutions nationwide,” said Arl Van Moore, Jr., M.D., FACR, chair of the ACR Board of Chancellors. "We are pleased that these types of research are leading to better diagnostic and radiation therapy techniques, which can help to improve disease detection, and save and extend lives.”

Recently, the ACR launched ACR Image Metrix, a contract research organization, which assists pharmaceutical and biotech manufacturers in the anticancer drug development using cutting-edge imaging to assist in the more rapid assessment of new anticancer compounds. "We are very encouraged by this recent report on the drop in cancer deaths and believe that the rapidly-expanding imaging technology and techniques for drug development will only continue to accelerate more anticancer drugs onto the market,” said Mike Morales, general manager for ACR Image Metrix.

The ACR's clinical research programs are among the largest recipients of U.S. medical research grants, and have an established reputation for handling large-scale clinical trials, involving up to 50,000 patients and the processing of some 50 million images. ACR Image Metrix will utilize the same infrastructure and expertise, but will provide support to pharmaceutical firms, biotechnology companies, and medical device manufacturers seeking U.S. Food and Drug Administration approval to bring new drugs, therapies, and medical devices to market.


Related Links:
American College of Radiology
ACR Image Metrix

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.